Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Int J Neurosci ; 130(9): 906-916, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31877070

RESUMO

Background: It has been proven that T cell immunoglobin and mucin domain (Tim)-4 and monocytes (Mo) are involved in regulation of immunity, which is important for the recovery of acute ischemic stroke (AIS).Methods: In this study, the expression of Tim-4 in both circulating Mo subtypes and plasma in 32 consecutive AIS patients and 32 control patients was assessed to determine their correlation with the clinical course and prognosis of AIS.Results: It was found that, compared to the control patients, the percentage of Tim-4 expression in overall Mo, classical Mo and non-classical Mo was significantly elevated after 2 and 5 days of stroke (p < 0.05), while it was promoted from 0 to 10 days of stoke in intermediate Mo (p < 0.05). Furthermore, Tim-4 expressions in non-classical Mo and intermediate Mo were obviously correlated with National Institutes of Health Stroke Scale (NIHSS) scores at 2 days of stroke (r = 0.351, p = 0.048; r = 0.358, p = 0.044, respectively). In poor outcome (PO) patients, the expression of Tim-4 in non-classical Mo was remarkably promoted at 2 days of stroke in comparison with non-PO patients (p < 0.05). More importantly, our results revealed a positive correlation between Tim-4 expression in non-classical Mo and interleukin (IL)-6 plasma levels in AIS patients without infection.Conclusion: In summary, our findings proved that Tim-4 expression in non-classical Mo could be an appropriate target for the prediction of the clinical course and prognosis in AIS patients.


Assuntos
Progressão da Doença , Interleucina-6/sangue , AVC Isquêmico , Proteínas de Membrana/metabolismo , Monócitos/metabolismo , Idoso , Feminino , Humanos , AVC Isquêmico/sangue , AVC Isquêmico/diagnóstico , AVC Isquêmico/imunologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Fator de Necrose Tumoral alfa/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA